Thus, in this review, we comprehensively examine the current landscape of biological markers for anti-PD-1/PD-L1 immunotherapy in NSCLC with an emphasis on some directions that warrant further investigation which can also deepen the understanding of clinicians and provide a reference for clinical practice. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.